Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Open in API
Filings indexed 962 across all filing types
Latest filing 2020-03-12 Regulatory Filings
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 12, 2020, reporting the issuance of a press release announcing financial results for the three months and year ended December 31, 2019. The text explicitly states that the press release is furnished as an exhibit and that the information is not deemed filed for certain regulatory purposes. The document itself is short (3526 characters) and primarily serves as a notification of the press release rather than containing detailed financial statements or analysis. According to the 'Menu vs Meal' rule, such a document is an announcement of a report rather than the report itself. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other categories and includes SEC Form 8-K filings announcing press releases or events.
2020-03-12 English
Annual Report 2019
Annual Report FY 2019
2020-03-12 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-03-09 English
Board/Management Information 2020
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 28, 2020, reporting on the approval of base salaries, bonuses, and equity awards for named executive officers of ADMA Biologics, Inc. It details compensation decisions made by the Compensation Committee and the Board of Directors. The content focuses on management compensation changes and appointments, which aligns with announcements about changes in senior management or board-related information. There is no financial statement or comprehensive financial performance data, so it is not an Annual Report or Interim Report. It is not a proxy statement or remuneration report but rather a current report on management compensation decisions. Therefore, the best fitting category is Board/Management Information (MANG). The document length and detail support a confident classification.
2020-03-05 English
Director's Dealing 2020
Director's Dealing
2020-03-04 English
Director's Dealing 2020
Director's Dealing
2020-03-04 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.